31 Jul 2015

UCB 2015 Half Year Report: Strong growth - at constant and actual exchange rates 

Read More
28 Jul 2015

UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint 

Read More
23 Jun 2015

Acquisition of own shares (June 23)

Read More
22 Jun 2015

Impact of earlier use of NEUPRO® (rotigotine transdermal patch) in Parkinson’s disease patients discussed at first EAN congress

Read More
15 Jun 2015

UCB announces first presentation of data from NEUPRO® (rotigotine transdermal patch) Phase 3 study in China at international congress

Read More
15 Jun 2015

Positive results from Phase 3 study evaluating CIMZIA® (certolizumab pegol) in DMARD-naïve rheumatoid arthritis patients

Read More
14 Jun 2015

Positive results from Phase 3 study evaluating CIMZIA® (certolizumab pegol) in DMARD-naïve rheumatoid arthritis patients

Read More
9 Jun 2015

UCB demonstrates scientific excellence with multiple presentations from immunology portfolio at EULAR 2015

Read More
8 Jun 2015

UCB announces submission of Kremers Urban's methylphenidate HCl ER bioequivalence study results to FDA 

Read More
30 Apr 2015

UCB's shareholder meeting today

Read More
Subscribe to